Heart rate control with if inhibitor, ivabradine, in Japanese patients with chronic heart failure–A randomized, double-blind, placebo-controlled phase II study–

Circulation Journal

Volumn 80, Issue 3, 2016, Pages 668-676

  Tsutsui, Hiroyuki ^a   Momomura, Shinichi ^b   Yamashina, Akira ^c   Ogawa, Hisao ^d   Shimokawa, Hiroaki ^e   Kihara, Yasuki ^f   Saito, Yoshihiko ^g   Hagiwara, Nobuhisa ^h   Ito, Hiroshi ⁱ   Ako, Junya ^j   Inomata, Takayuki ^j   Tanaka, Takashi ^k   Kawasaki, Yasushi ^k  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g NARA MEDICAL UNIVERSITY   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j KITASATO UNIVERSITY   (Japan)

^k ONO PHARMACEUTICAL CO   (Japan)

more..

Author keywords

Chronic heart failure; Double blind placebo controlled trial; If inhibitor; Left ventricular ejection fraction; Resting heart rate

Indexed keywords

IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUS RHYTHM; AGED; CHRONIC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HEART RATE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL;

AGED; BENZAZEPINES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED;

EID: 84959018072     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-1112     Document Type: Article

References (29)

1. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: The Framingham Study. Am Heart J 1987; 113: 1489-1494.
2. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan: Report from the CHART studies. Circ J 2015; 79: 2396-2407.
3. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 1992; 20: 1092-1098.
4. Ingwall JS, Weiss RG. Is the failing heart energy starved?: On using chemical energy to support cardiac function. Circ Res 2004; 95: 135-145.
5. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-312.
6. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-1482.
7. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group. Circulation 1996; 94: 2800-2806.
8. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
9. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in- Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
10. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794.
11. Komajda M. Current challenges in the management of heart failure. Circ J 2015; 79: 948-953.
12. Sulfi S, Timmis AD. Ivabradine: The first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract 2006; 60: 222-228.
13. Deedwania P. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs 2013; 73: 1569-1586.
14. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 11: 875-885.
15. Borer JS, Böhm M, Ford I, Komajda M, Tardif JC, O’Maera E, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: The SHIFT Study. Eur Heart J 2012; 33: 2813-2820.
16. Tardif JC, O’Maera E, Komajda M, Böhm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J 2011; 33: 2507-2515.
17. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Heart J 2011; 32: 2395-2404.
18. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22.
19. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, et al. Effects of outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of betablocker dose? J Am Coll Cardiol 2012; 59: 1938-1945.
20. Bocchi EA, Böhm M, Borer JS, Ford I, Komajda M, Swedberg K, et al. Effect of combining ivabradine and β-blockers: Focus on the use of carvediol in the SHIFT population. Cardiology 2015; 131: 218-224.
21. Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113: 497-503.
22. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. Int J Cardiol 2013; 170: 182-188.
23. Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Böhm M, et al. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: An analysis from SHIFT. Eur J Heart Fail 2014; 16: 426-434.
24. Reil JC, Robertson M, Ford I, Borer JS, Komajda M, Swedberg K, et al. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. Eur J Heart Fail 2013; 15: 1044-1052.
25. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: Insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296-1303.
26. Komajda M, Böhm M, Borer JS, Robertson M, Manolis AJ, Tavazzi L, et al. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 2014; 16: 810-816.
27. Matsuzaki M, Ishii M, Izumi T, Ito H, Ito H, Ueda Y, et al. Guidelines for treatment of chronic heart failure (JCS 2010) (updated September 13, 2013). http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf (accessed October 1, 2015).
28. Hsu JC. The factor analytic approach to simultaneous inference in the general linear model. J Comput Graph Stat 1992; 1: 151-168.
29. Bagriy AE, Schukina EV, Samoilova OV, Pricolota OA, Malovichko SI, Pricolota AV, et al. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Adv Ther 2015; 32: 108-119.